Therapeutic Areas

Oncology

Digital Biomarkers for Oncology Research

Accelerating Discovery

Talk to an Expert

Koneksa’s digital biomarkers are bringing much-needed improvements to the speed, precision, and patient accessibility of oncology trials.

Remote digital biomarkers in oncology
Digital Biomarkers for Oncology Research

Remote digital biomarkers in oncology open the door to participation in clinical trials, even for patients dealing with the challenges of their disease and treatment side effects, including fatigue and travel-based difficulties.

​With our patient-centric digital biomarker solutions and flexible, device-agnostic SaaS platform, we work with you from the design stage to ensure you get the sharp endpoints needed to stay on top of critical aspects of patient health status.

Some of the oncology areas in which we have worked in include:

Lung

Gastrointestinal cancer

Gastrointestinal

Cervical cancer

Cervical

Ecologically Valid Measures

Ecologically Valid Measures for Deeper Insights

As the leaders in digital biomarkers, Koneksa is proud to play a crucial role in the evolution of oncology trials.

Through our research experience and involvement with patient advocacy groups, we have gained a nuanced understanding of patients’ needs. That’s why our solutions are designed to capture a high volume of data obtained during patients’ everyday lives, providing crucial information about the impact of treatments while making it easier for patients to participate.

Koneksa’s oncology solutions facilitate the tracking of measures like heart rate variability (HRV), walking speed, temperature, blood pressure, and step count on a 24/7 basis, eliminating the variability introduced by performance differences in clinic versus at home, and over the course of a day.

Koneksa’s oncology solutions

Smarter Oncology Trials Start Here

Koneksa delivers digital biomarkers and expert support to help you capture the measures that matter—enabling faster, more accurate decisions and better outcomes for patients.

Our science-driven approach and ecologically valid measures help you understand the true impact of your treatment:

Koneksa Watch

Signs, not symptoms

Digital biomarkers provide objective evidence for how patients are doing

Continuous Capabilities

Continuous Capabilities

Ongoing data collection allows for insights that would be impossible to glean solely from sporadic clinic visits

progression

Progression

Frequent measures let you closely track changes in health status over time

The Data You Need, When It Matters Most

In a recent Koneksa study, daily step count predicted oncology hospitalizations—while traditional quality-of-life assessments did not. When study patients are improving—or declining—you need to know immediately.

Read Our Step Count Study
footprintNew digital tool for oncology symptom tracking
heart pulseImprove clinician-participant communication and safety monitoring
Digital EndpointsScalable, patient-centric innovation in cancer research

More from Koneksa

Found 6 Results
Page 1 of 2
Article

The Playbook Digest: The New Digital Medicine Manual & Its Impact in Oncology

When smartphone-powered fitness trackers emerged, clinical researchers, life science professionals, and academic researchers immediately saw the potential for real-time data synchronization and data summary visualizations for end users.1 Their interest…

Download
Article

Tolerability in Oncology: FDA and ASCO Agree With Koneksa, It’s Vital to Measure It

Recently, the Food and Drug Administration (FDA) and American Society of Clinical Oncology (ASCO) held a joint virtual workshop on clinical outcome assessments in clinical trials for cancer treatments. This…

Download
Article

Digital Phenotypes and Biomarkers for Oncology Patients: Koneksa at IO360

As part of Koneksa’s participation in the recent Immuno-Oncology Conference (IO360), CEO Chris Benko summarized Koneksa’s work in oncology. In the often technical world of oncology research, the human patients…

Download